4//SEC Filing
JENSEN JESSICA D. 4
Accession 0001104659-23-129773
CIK 0001811764other
Filed
Dec 26, 7:00 PM ET
Accepted
Dec 27, 5:39 PM ET
Size
16.3 KB
Accession
0001104659-23-129773
Insider Transaction Report
Form 4
JENSEN JESSICA D.
EVP Clinical Development
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2023-12-27−125,553→ 0 totalExercise: $6.97Exp: 2026-07-20→ Common Stock (125,553 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-12-27−461,250→ 0 totalExercise: $8.47Exp: 2027-07-06→ Common Stock (461,250 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-12-27−13,766→ 0 totalExercise: $7.91Exp: 2028-04-01→ Common Stock (13,766 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-12-27−136,055→ 0 totalExercise: $6.78Exp: 2029-03-28→ Common Stock (136,055 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-12-27−213,301→ 0 totalExercise: $8.13Exp: 2028-03-29→ Common Stock (213,301 underlying)
Footnotes (2)
- [F1]This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 2, 2023, by and among POINT Biopharma Global Inc. (the "Issuer"), Eli Lilly and Company (the "Parent"), and Yosemite Falls Acquisition Corporation, a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share"). After completion of the cash tender offer, Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 27, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $12.50 in cash (the "Merger Consideration"), without interest and less any applicable tax withholding.
- [F2]Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.
Documents
Issuer
POINT Biopharma Global Inc.
CIK 0001811764
Entity typeother
Related Parties
1- filerCIK 0001868742
Filing Metadata
- Form type
- 4
- Filed
- Dec 26, 7:00 PM ET
- Accepted
- Dec 27, 5:39 PM ET
- Size
- 16.3 KB